Depression risk detected by measuring heart rate changes

Embargo until: 00.05 CEST (Vienna) Saturday 12th September 2020

Type of study: not peer-reviewed/experimental study/people

For the first time doctors have shown that measuring changes in 24-hour heart rate can reliably indicate whether or not someone is depressed. In practical terms, this may give clinicians an objective “early warning” of potential depression, as well as a rapid indication whether or not treatment is working, so opening the way to more rapid and responsive treatment. Presenting results of this pilot study at the ECNP virtual congress, lead researcher, Dr Carmen Schiweck (Goethe University, Frankfurt) said “Put simply, our pilot study suggests that by just measuring your heart rate for 24 hours, we can tell with 90% accuracy if a person is currently depressed or not”.

Scientists have known that heart rate is linked to depression, but until now they have been unable to understand exactly how one is related to the other. In part this is because while heart rates can fluctuate quickly, depression both arrives and leaves over a longer period, with most treatments taking months to take effect. This makes it difficult to see whether or not changes in one’s depressive state might be related to heart rate.

“Two innovative elements in this study were the continuous registration of heart rate for several days and nights, and the use of the new antidepressant ketamine, which can lift depression more or less instantly. This allowed us to see that average resting heart rate may change quite suddenly to reflect the change in mood”, said Carmen Schiweck.

Ketamine has a history as both an anaesthetic and a party drug (a drug of abuse). However in December last year it was licenced to treat major depression in Europe, after having been introduced in the USA a few months earlier. Traditional antidepressants can take weeks to show an effect, in contrast ketamine is rapid acting, with results often being seen in minutes.

As Carmen Schiweck said “We knew that something was going on to link heart rate to psychiatric disorders, but we didn’t know what it was, and whether it would have any clinical relevance. In the past researchers had shown that depressed patients had consistently higher heart rates and lower heart rate variability, but because of the time it takes to treat depression it had been difficult to follow up and relate any improvement to heart rate. But when we realized that ketamine leads to a rapid improvement in mood, we knew that we might be able to use it to understand the link between depression and heart rate”.

Dr Schiweck performed this work in the Mind Body Research group at KU Leuven, Belgium, with Dr Stephan Claes as the principal investigator. The team worked with a small sample of 16 patients with Major Depressive Disorder, none of who had responded to normal
treatment, and 16 healthy controls. They measured their heartrates for 4 days and 3 nights, and then the volunteers with depression were given either ketamine treatment or a placebo.

“We found that those with depression had both a higher baseline heart rate, and a lower heart rate variation, as we expected. On average we saw that depressed patients had a heart rate which was roughly 10 to 15 beats per minutes higher than in controls. After treatment, we again measured the heart rates and found that both the rate and the heartrate fluctuation of the previously depressed patients had changed to be closer to those found in the controls”.

The most striking finding was that the scientists were able to use 24-hour heart rate as a “biomarker” for depression. Heart rates were measured using a wearable mini-ECG. The data was fed to an Artificial Intelligence programme, which was able to classify nearly all controls and patients correctly as being depressed or healthy.

“Normally heart rates are higher during the day and lower during the night. Interestingly, it seems that the drop in heart rate during the night is impaired in depression. This seems to be a way of identifying patients who are at risk to develop depression or to relapse.” said Carmen Schiweck.

The team also found that patients with a higher resting heart rate responded better to the treatment with Ketamine, which may help identify which patients are likely to respond to which treatment.

Carmen Schiweck said “We need to remember that this is a small proof-of-concept study: 6 of our of our 16 initial patients responded to treatment with at least a 30% reduction on the Hamilton Rating scale for depression, so we need to repeat the work with a larger, antidepressant free sample. Our next step is to follow up depressed patients and patients who are in remission, to confirm that the changes we see can be used as an early warning system”.

Commenting, Professor Brenda Penninx of the Department of Psychiatry at Amsterdam University Medical Centre, said:

“This is an innovative proof-of-concept study. My own group had previously studied short-term heart rate variability in over a thousand depressed patients and controls, and we did not detect a consistent differentiation, and found antidepressants to have more impact than depression status itself. However, this study monitored heart rate variability in the ambulatory setting for several days and nights, which gives unique night and day information on the autonomic nervous system. It needs to be examined whether these interesting findings hold in larger, more diverse treatment settings”.

Professor Penninx was not involved in this work, this is an independent comment.
Funding: this research was funded by a TGO-IWT Grant from Belgium. KU Leuven worked with imec to use the heart monitor, but no funding was received from imec.

Ends

Notes for Editors

European College of Neuropsychopharmacology (ECNP)

The ECNP is an independent scientific association dedicated to the science and treatment of disorders of the brain. It is the largest non-institutional supporter of applied and translational neuroscience research and education in Europe. Website: www.ecnp.eu

The 33rd annual ECNP Congress – ECNP Virtual - takes place from 12th to 15th September. It is Europe’s premier scientific meeting for disease-oriented brain research. In 2020 it is a virtual congress. The regular congress annually attracting up to 6,000 neuroscientists, psychiatrists, neurologists and psychologists from around the world. Congress website: https://www.ecnp.eu/Congress2020 The 2021 congress is scheduled to take place in Lisbon next September.

Conference abstract: Heart rate and heart rate variability as trait or state marker for depression? Insights from a ketamine treatment paradigm

C. Schiweck1, E. Lutin2, W. De Raedt3, M. Morrens4, V. Coppens4, C. Van Hooft5, A. Reif6, E. Vrieze6, S. Claes6

1Goethe University, Department of Psychiatry Psychosomatics and Psychotherapy, Frankfurt am Main, Germany ; 2KU Leuven, ESAT Electrical Engineering, Leuven, Belgium ; 3Imec, Mental Health, Heverlee, Belgium ; 4University of Antwerp, CAPRI Collaborative Antwerp Psychiatric Research Institute, Antwerp, Belgium ; 5UZ Leuven, Department of Neurosciences and Psychiatry, Leuven, Belgium

Background

Psychophysiological abnormalities are characteristic of Major Depressive Disorder (MDD) [1]. Recently, Heart Rate (HR) and HR Variability (HRV) have been used in an attempt to identify trait or even state markers for MDD [2,3]. However, recent classification efforts have ignored circadian rhythm variation in depression and assessment of state marker potential was hampered by time variant covariates. We here use an innovative study design with the rapid-acting anti-depressant ketamine to assess the potential of HR/HRV as state marker for depression. The aim of the present study is to assess the potential of real-life psychophysiological measures as trait and/or state markers for depression.

Methods

We present data on 16 treatment resistant diagnosed MDD patients and 16 age and sex matched healthy controls. All participants completed a baseline phase of psychophysiological recording (4 days/3 nights). Subsequently patients received a single treatment with ketamine or placebo, aiming to improve mood. Following treatment, psychophysiological monitoring was repeated for patients. We assessed circadian rhythm differences of HR and the root mean square of successive differences (RMSSD) as surrogate marker for parasympathetic nervous system activity with state of the art wearable technology. Statistical analysis was performed using linear mixed models including a random intercept, and harmonic regression terms using cosines/sines wavelet functions to address circadian rhythm variations. Binary logistic regression with leave one out cross validation (LOOCV) was performed for classification purposes. HR/RMSSD change was tested for treatment response prediction.

Results

Higher baseline HR (t=5.62, p<0.001) and lower RMSSD (t=-4.96,p<0.001) was observed in patients with depression. A marked reduction in amplitude for HR showed significant blunting of circadian rhythm variation throughout the day and less recovery at night. This was evidenced by significant interactions for harmonic regression terms with group for HR (all b>0.026, t>4.320, p<0.001) and RMSSD (all b<-0.077, t>3.13, p<0.002). Excellent classification accuracy was achieved,
particularly during night (90.6%), with 15 of 16 controls and 14 of 16 patients correctly classified using the log of HR. A positive association between baseline HR and treatment response (Spearman’s r = 0.55, p = 0.046) also pointed towards better treatment outcomes in patients with higher HR. Additionally, HR decreased significantly following treatment (HR: b = 0.025, t = 5.77, p < 0.001), but no significant change was observed for RMSSD (b = 0.021, t = 1.047, p = 0.295). HR changes were however not related to depression states: Post hoc analysis showed that before treatment, HR was positively correlated with depression severity (Spearman’s r = 0.59, p = 0.03), whereas post treatment, this effect was abolished (Spearman’s r = -0.04, p = 0.9).

**Conclusion**

Baseline HR levels remained significantly higher and RMSSD significantly lower in MDD patients, at all times of a 24-hour day. Interestingly, particularly HR at night showed high classification accuracy of patients and thus has potential as trait marker for depression. While we here show a that HR predicts treatment response, in this study, we cannot affirm its role as state marker. Our findings have exciting implications for treatment selection. Future longitudinal studies with larger sample sizes are needed to assess whether HR is a good state marker for traditional antidepressant treatment approaches.

**References**


This was funded by a TGO-IWT Grant from Belgium.